### IN THIS ISSUE

Highlighted research articles .................................. 471

### NEWS IN BRIEF

Important news stories affecting the community .................. 474

### NEWS IN DEPTH

Q&A: Powel Brown on Cancer Prevention Research .............. 477

Two Drugs Deemed Breakthrough Therapies ................. 478

### RESEARCH WATCH

Selected highlights of recent articles of exceptional significance from the cancer literature .............. 479

### ONLINE

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

### VIEWS

In The Spotlight

G34, Another Connection between MYCN and a Pediatric Tumor .......... 484
M. Huang and W.A. Weiss
See article, p. 512

Déjà Vu: EGF Receptors Drive Resistance to BRAF Inhibitors .......... 487
M.R. Girotti and R. Marais
See article, p. 520

Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer .............. 491
R. Chen and E.A. Sweet-Cordero
See article, p. 548

Discovering What Makes STAT Signaling TYK in T-ALL ........... 494
L. Fontan and A. Melnick
See article, p. 564

### In Focus

A Tale of Metabolites: The Cross-Talk between Chromatin and Energy Metabolism .......... 497
B. Martinez-Pastor, C. Cosentino, and R. Mostoslavsky

### REVIEW

Molecular Dissection of Microsatellite Instable Colorectal Cancer .......... 502
E. Vilar and J. Tabernero

### RESEARCH BRIEF

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN .............. 512
Précis: Histone variant H3.3 glycine-34 mutations induce differential genome-wide histone H3 lysine 36 trimethylation and lead to upregulation of MYCN in the developing forebrain.
See commentary, p. 484

### RESEARCH ARTICLES

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas .......... 520
Précis: Lineage-specific HER3 upregulation and ligand-dependent HER2/HER3 activation confer resistance to MAPK pathway inhibitors in BRAF-mutant thyroid cancer cells.
See commentary, p. 487

Précis: Transcriptional derepression of PDGFRβ in response to EGFR inhibition renders EGFR-mutant glioblastomas dependent on PDGFRβ for survival.

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS-Mutant Lung Cancer. M. Molina-Arcas, D.C. Hancock, C. Sheridan, M.S. Kumar, and J. Downward

Précis: KRAS-mutant NSCLC cells are selectively sensitive to inhibition of IGF1R, which is required for KRAS-mediated activation of PI3K signaling.

See commentary, p. 491


Précis: Metastasis-incompetent tumors systemically reprogram bone marrow–derived myeloid cells in the premetastatic niche to produce TSP-1 to suppress metastatic outgrowth.

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- Old Drug Learns New Tricks for Lymphoma
- Startup Bets on Cancer Immunotherapy
- Devil Is in Details for Data Transparency
- PI3K Inhibitor Shows Promise in Early Trial
- Teaming Up for a Companion Diagnostic
- AKT Inhibitors Take Steps Forward
CANCER DISCOVERY

3 (5)


Updated version  Access the most recent version of this article at: http://cancerdiscovery.aacrjournals.org/content/3/5

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.